| Citation: |
WU Qiong, MA Junyan, DONG Liang, LI Chunyang, WANG Zhiwu. Prediction Model of Treatment Effect of Anlotinib on Extensive-stage Small Cell Lung Cancer Based on Combination of Disease and Syndrome Information[J]. Cancer Research on Prevention and Treatment, 2023, 50(5): 483-489. DOI: 10.3971/j.issn.1000-8578.2023.22.1373
|
To construct a nomogram prediction model for the treatment effect of anlotinib with the participation of traditional Chinese medicine syndrome elements on the patients with extensive-stage small cell lung cancer (ES-SCLC) who previously received multiple lines of chemotherapy.
The clinical data of 127 patients with ES-SCLC who received at least two cycles of anlotinib treatment were retrospectively studied. Kaplan-Meier method was used to analyze the relationship between each factor and the overall survival time. Cox regression analysis was applied to screen the independent influencing factors of the prognosis of patients with ES-SCLC. R language was employed to build a nomogram prediction model, C-index was used to evaluate the model, and calibration curve was adopted to verify the accuracy of the model.
Age, PS score, brain metastases, qi deficiency syndrome, yin deficiency syndrome, and blood stasis syndrome were related risk factors for ES-SCLC treated with anlotinib. PS score, brain metastasis, and blood stasis syndrome were independent prognostic factors. On the basis of these three independent influencing factors, a nomogram model was established to predict the prognosis of patients with ES-SCLC treated with anlotinib. The predicted risk was close to the actual risk, showing a high degree of coincidence.
The nomogram model established with PS score, blood stasis syndrome elements, and brain metastasis as independent factors can predict the prognosis of patients with ES-SCLC receiving second- and third-line treatment of anlotinib.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Poirier JT, George J, Owonikoko TK, et al. New approaches to SCLC therapy: from the laboratory to the clinic[J]. J Thorac Oncol, 2020, 15(4): 520-540. doi: 10.1016/j.jtho.2020.01.016
|
| [2] |
Dingemans A-M C, Früh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2021, 32(7): 839-853. doi: 10.1016/j.annonc.2021.03.207
|
| [3] |
Gözel S, Sumbul A, Sedef AM, et al. Influence of Creatinine Clearance on Survival Parameters in Small Cell Lung Cancer Treated with Cisplatin-Based Chemotherapy Regimen: Topic: Drug Treatment Alone and in Combination with Radiotherapy[J]. J Thoracic Oncol, 2017, 12(1): s701-s702. doi: 10.1016/j.jtho.2016.11.921
|
| [4] |
Li D, Wei G, Li L, et al. Bronchopleural fistula in squamous cell lung cancer following anlotinib treatment: A case report[J]. Mol Clin Oncol, 2019, 11(6): 595-598. http://www.xueshufan.com/publication/2981329240
|
| [5] |
中国医师协会肿瘤医师分会, 中国临床肿瘤学会血管靶向治疗专家委员会, 中国抗癌协会肿瘤靶向治疗专业委员会. 盐酸安罗替尼治疗晚期肺癌中国专家共识(2020版)[J]. 中华肿瘤杂志, 2020, 42(10): 807-816.
Oncologist Branch of Chinese Medical Doctor Association, Expert Committee of Vascular Targeted Therapy of Chinese Society of Clinical Oncology, Professional Committee of Targeted Therapy of Cancer of Chinese Anti-Cancer Association. Chinese expert consensus on the treatment of advanced lung cancer by antirotinib hydrochloride (2020 edition)[J]. Zhonghua Zhong Liu Za Zhi, 2020, 42(10): 807-816.
|
| [6] |
Zhang Y, Jia B, Li J, et al. Anlotinib in treatment of an elderly patient with recurrent advanced SCLC[J]. Tumori, 2020, 106(6): NP36-NP40. doi: 10.1177/0300891619900673
|
| [7] |
张国伟, 程瑞瑞, 牛媛媛, 等. 安罗替尼单药治疗89例老年广泛期小细胞肺癌的疗效和安全性分析[J]. 肿瘤学杂志, 2022, 28(6): 479-484. https://www.cnki.com.cn/Article/CJFDTOTAL-XHON202206007.htm
Zhang GW, Cheng RR, Niu YY, et al. Efficacy and Safety of antirotinib in the treatment of 89 elderly patients with extensive small cell lung cancer[J]. Zhong Liu Xue Za Zhi, 2002, 28(6): 479-484. https://www.cnki.com.cn/Article/CJFDTOTAL-XHON202206007.htm
|
| [8] |
王静怡, 董量, 付浩宇, 等. 安罗替尼二三线治疗的广泛期小细胞肺癌患者预后分析[J]. 中国临床医生杂志, 2021, 49(1): 38-41. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLYS202101012.htm
Wang JY, Dong L, Fu HY, et al. Prognosis analysis of patients with extensive small cell lung cancer treated with second or third line antirotinib[J]. Zhongguo Lin Chuang Yi Sheng Za Zhi, 2021, 49(1): 38-41. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLYS202101012.htm
|
| [9] |
卢美君, 赵燕仪, 康马飞. 影响安罗替尼临床疗效和预后的多因素分析[J]. 现代肿瘤医学, 2022, 30(10): 1831-1835. doi: 10.3969/j.issn.1672-4992.2022.10.023
Lu MJ, Zhao YY, Kang MF. Analysis of the factors influencing the clinical efficacy and prognosis of androtinib[J]. Xian Dai Zhong Liu Yi Xue, 2022, 30(10): 1831-1835. doi: 10.3969/j.issn.1672-4992.2022.10.023
|
| [10] |
Li H, Liu Y, Liu X, et al. A novel multi-target tyrosine kinase inhibitor anlotinib combined with irinotecan has in-vitro anti-tumor activity against human small-cell lung cancer[J]. Anti-Cancer Drugs, 2020, 31(10): 1057-1064. doi: 10.1097/CAD.0000000000000969
|
| [11] |
中华人民共和国国家卫生健康委员会. 原发性肺癌诊疗指南(2022年版)[J]. 中国合理用药探索, 2022, 19(9): 1-28. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYS202209001.htm
National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary lung cancer (2022 edition)[J]. Zhongguo He Li Yong Yao Tan Suo, 2022, 19(9): 1-28. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYS202209001.htm
|
| [12] |
朱文锋. 证素辨证学[M]. 第1版. 北京: 人民卫生出版社, 2008: 88-90.
Zhu WF. Syndrome element Differentiation[M]. 1st Ed. Beijing: People's Medical Publishing House, 2008: 88-90.
|
| [13] |
王蓉, 申洹浣, 谢书阳, 等. 不同年龄组小细胞肺癌的临床特征与预后影响因素分析[J]. 中国医院统计, 2022, 29(4): 246-252, 256. https://www.cnki.com.cn/Article/CJFDTOTAL-JTYY202204002.htm
Wang R, Shen HH, Xie SY, et al. Analysis of clinical features and prognostic factors of small cell lung cancer in different age groups[J]. Zhongguo Yi Yuan Tong Ji, 2022, 29(4): 246-252, 256. https://www.cnki.com.cn/Article/CJFDTOTAL-JTYY202204002.htm
|
| [14] |
中华人民共和国卫生部. 中药新药临床研究指导原则(试行)[M]. 北京: 中国医药科技出版社, 2002: 216-224.
Ministry of Health of the People's Republic of China. Guidelines for clinical research of New Chinese Medicine (Trial)[M]. Beijing: China Medical Science and Technology Press, 2002: 216-224.
|
| [15] |
王晶, 李凯. 小细胞肺癌治疗中的抗血管生成药物研究进展[J]. 中华肿瘤杂志, 2020, 42(8): 624-628. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ202101012.htm
Wang J, Li K. Research progress of anti-angiogenic drugs in the treatment of small cell lung cancer[J]. Zhonghua Zhong Liu Za Zhi, 2020, 42(8): 624-628. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ202101012.htm
|
| [16] |
Montanino A, Manzo A, Carillio G, et al. Angiogenesis inhibitors in small cell lung cancer[J]. Front Oncol, 2021, 11: 655316.
|
| [17] |
Xu Q, Gu J, Lv Y, et al. Angiogenesis for tumor vascular normalization of Endostar on hepatoma 22 tumor-bearing mice is involved in the immune response[J]. Oncol Lett, 2018, 15(3): 3437-3446. doi: 10.3892/ol.2018.7734/download
|
| [18] |
Rodríguez-Remírez M, del Puerto-Nevado L, Fernández-Aceñero MJ, et al. Targeting galectin-1 by aflibercept strongly enhances its antitumor effect in neuroendocrine carcinomas[J]. Neuroendocrinology, 2021, 111(1-2): 146-157. http://pubmed.ncbi.nlm.nih.gov/31991407/
|
| [19] |
Gao X, Peng L, Zhang L, et al. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer[J]. J Cancer Res Clin Oncol, 2022, 148(10): 2661-2671. doi: 10.1007/s00432-021-03848-4
|
| [20] |
肖琳, 王志武, 宣立功, 等. 晚期非小细胞肺癌安罗替尼治疗后中医证型与近期疗效相关性因素的分析[J]. 辽宁中医杂志, 2022, 49(9): 74-78. https://www.cnki.com.cn/Article/CJFDTOTAL-LNZY202209021.htm
Xiao L, Wang ZW, Xuan LG, et al. Analysis of correlation factors between TCM syndrome type and short-term curative effect after treatment of advanced non-small cell lung cancer with antirotinib[J]. Liaoning Zhong Yi Za Zhi, 2022, 49(9): 74-78. https://www.cnki.com.cn/Article/CJFDTOTAL-LNZY202209021.htm
|
| [21] |
周卫东, 袁庆, 艾瑛, 等. 不同中医证型肺鳞癌患者的化疗疗效及其中医干预疗效[J]. 实用医学杂志, 2020, 36(5): 677-681. https://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ202005028.htm
Zhou WD, Yuan Q, Ai Y, et al. Therapeutic effect of chemotherapy and TCM intervention in patients with lung squamous cell carcinoma with different TCM syndroms[J]. Shi Yong Yi Xue Za Zhi, 2020, 36(5): 677-681. https://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ202005028.htm
|
| [22] |
芦希艳, 姚家久, 赵宁侠. 中医辨证辅助化疗治疗非小细胞肺癌的临床疗效及对患者免疫功能和预后的影响[J]. 癌症进展, 2022, 20(8): 797-799, 804. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ202208005.htm
Lu XY, Yao JJ, Zhao NX. Clinical efficacy of TCM syndrome differentiation and adjuvant chemotherapy in the treatment of non-small cell lung cancer[J]. Ai Zheng Jin Zhan, 2002, 20(8): 797-799, 804. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ202208005.htm
|
| [23] |
Chen T, Tang M, Xu X, et al. Inflammation-based prognostic scoring system for predicting the prognosis of advanced small cell lung cancer patients receiving anlotinib monotherapy[J]. J Clin Lab Anal, 2022, 36(12): e24772.
|
| [24] |
Wu D, Nie J, Hu W, et al. A phaseⅡ study of anlotinib in 45 patients with relapsed small cell lung cancer[J]. Int J Cancer, 2020, 147(12): 3453-3460. http://pubmed.ncbi.nlm.nih.gov/32557583/
|
Figures(3) / Tables(4)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: